The US Food and Drug Administration (FDA) has approved Investigational New Drug (IND) application submitted by Airway Therapeutics to develop AT-100 (rhSP-D) for treating patients with Covid-19.
Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to develop AT-100 (rhSP-D) as a treatment for COVID-19. Airway is leveraging the FDA's Coronavirus Treatment Acceleration Program (CTAP) that is aimed at evaluating new treatment options for COVID-19.
Attorneys who weighed in to the Colorado Supreme Court on a proposal to require equity, diversity and inclusivity training as part of continuing legal education were largely in favor of the mandate, saying lawyers of color and women bear the brunt of unprofessional conduct. Itâs well established that bias is as natural as we breathe, and that equity is a lifelong journey where we never arrive, said Nathifa Miller, co-chair of the committee that developed the policy, at a Tuesday hearing with the seven justices. Thatâs where we get fooled. We think weâve arrived. And the key is education.â